Takeda Pharmaceutical Co (Takeda Pharmaceutical Co) Debt-to-Revenue : 1.05 (As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

What is Takeda Pharmaceutical Co Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Takeda Pharmaceutical Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $2,572 Mil. Takeda Pharmaceutical Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $29,822 Mil. Takeda Pharmaceutical Co's annualized Revenue for the quarter that ended in Dec. 2023 was $30,870 Mil. Takeda Pharmaceutical Co's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 1.05.

Takeda Pharmaceutical Co Debt-to-Revenue Historical Data

The historical data trend for Takeda Pharmaceutical Co's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Takeda Pharmaceutical Co Debt-to-Revenue Chart

Takeda Pharmaceutical Co Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Debt-to-Revenue

Get a 7-Day Free Trial

2.74

1.55

1.45

1.22

1.09

Takeda Pharmaceutical Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Revenue	Get a 7-Day Free Trial															0.98	1.15	1.12	1.12	1.05

Competitive Comparison of Takeda Pharmaceutical Co's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Takeda Pharmaceutical Co's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Takeda Pharmaceutical Co's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Takeda Pharmaceutical Co's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Takeda Pharmaceutical Co's Debt-to-Revenue falls into.

Takeda Pharmaceutical Co Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Takeda Pharmaceutical Co's Debt-to-Revenue for the fiscal year that ended in Mar. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(2540.693	+	30245.481)	/	30131.292
	=	1.09

Takeda Pharmaceutical Co's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(2571.803	+	29822.387)	/	30870.244
	=	1.05

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2023) Revenue data.

Takeda Pharmaceutical Co Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Takeda Pharmaceutical Co's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Takeda Pharmaceutical Co (Takeda Pharmaceutical Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Takeda Pharmaceutical Co Ltd (NYSE:TAK) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

TKPHF:USA TAK:Mexico 4502:Japan 4502:Japan 4502:Japan 4502:Japan TKDA:Germany TKD:Germany TKD:Germany TAKP34:Brazil

Address

1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, JPN, 103-8668

Website

https://www.takeda.com

Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4 trillion in fiscal 2022. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the U.S., 20% from Japan, 20% from Europe and Canada.